NEUROCRINE BIOSCIENCES INC Convertible Debt, Noncurrent
NEUROCRINE BIOSCIENCES INC (NBIX) had Convertible Debt, Noncurrent of $169.50 million as of 2023-03-31, per its 10-Q filed 2023-05-03.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:ConvertibleDebtNoncurrent · last filed 2023-05-03
- 2023-03-31: Convertible Debt, Noncurrent $169.50M.
- 2022-12-31: Convertible Debt, Noncurrent $0.00.
- 2022-09-30: Convertible Debt, Noncurrent $0.00.
- 2022-06-30: Convertible Debt, Noncurrent $169.00M.
| Period end | Convertible Debt, Noncurrent | Convertible Debt, Noncurrent as first filed |
|---|---|---|
| 2023-03-31 | $169.50M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $0.00 10-Q · filed 2023-05-03 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $169.00M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $377.70M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $335.10M 10-K · filed 2023-02-09 | |
| 2021-09-30 | $330.70M 10-Q · filed 2021-11-01 | |
| 2021-06-30 | $326.30M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $322.00M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $317.90M 10-K · filed 2022-02-11 | |
| 2020-09-30 | $425.00M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $419.50M 10-Q · filed 2020-08-03 | |
| 2020-03-31 | $414.10M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $0.00 10-K · filed 2021-02-05 | $408.81M 10-K · filed 2020-02-07 |
| 2019-09-30 | $403.59M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $398.47M 10-Q · filed 2019-07-29 | |
| 2019-03-31 | $393.44M 10-Q · filed 2019-04-29 | |
| 2018-12-31 | $388.50M 10-K · filed 2020-02-07 | |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $378.88M 10-Q · filed 2018-07-31 | |
| 2018-03-31 | $374.21M 10-Q · filed 2018-04-30 | |
| 2017-12-31 | $369.62M 10-K · filed 2019-02-08 | |
| 2017-09-30 | $365.11M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $360.68M 10-Q · filed 2017-08-03 | |
| 2016-12-31 | $0.00 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |